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INTRODUCTION
As in humans, cancer is one of the most common reasons for death 
in dogs. Surgery, chemotherapy, and radiation therapy are the most 
commonly used treatment options in veterinary oncology but 
in parallel with the human situation new approaches are needed 
especially for advanced metastatic solid tumors which are often 
incurable with traditional therapies.
Dogs with spontaneous cancer serve as a good model for human 
cancers.1–4 Dogs share the same environment with their owners, 
their immune system is intact, their size is close to humans and 
cancer progression is spontaneous. These are key advantages over 
laboratory rodents. Critically, like cancer in human patients but in 
contrast to rodent models, cancer arising in dogs develops over 
several years, resulting in similar complexity, clonality, and immune 
suppression as seen in man. The biological behavior also has many 
similarities, including metastatic patterns, relapse, and treatment 
resistance. In addition, the same cancer-associated genes and histo-
logical features have been found in both species.2,5
Oncolytic virotherapy, where replication competent viruses are armed 
with immunostimulatory transgenes, is a promising new treatment 
approach.6–9 Before directly killing cancer cells, immunostimulatory genes 
are expressed by infected cells to awaken the host immune system, which 
is suppressed by the tumor microenvironment in progressing clinically 
evident tumors. Then, infected tumor cells are killed by oncolysis, releasing 
a broad variety of tumor antigens into the environment for the adaptive 
immune system to sample.
The oncolytic Western Reserve vaccinia virus used in the present 
study, vvdd-hCD40L-tdTomato,10 has thymidine kinase (TK) and vac-
cinia growth factor (VGF) deletions to render the virus tumor  specific. 
Removal of TK makes the virus dependent on cellular nucleotides, 
typically found in abundance in tumors.8 As an important biosafety 
improvement over previous designs, our virus features a 150 bp dele-
tion of TK instead of mere disruption of the open reading frame of 
the gene by the transgene cassette, rendering reversion to wild type 
by recombination impossible.10 Deletion of VGF, the viral analogue of 
cellular epidermal growth factor (EGF), renders the virus dependent on 
an activated EGFR-ras pathway, which is a common feature of human 
solid tumors,7,8 and also found in canine tumors.11 In addition to TK and 
VGF disruptions which increase virus safety and biosafety, the virus 
expresses tdTomato, a red fluorescent protein facilitating in vivo track-
ing of virus-infected cells,12 as well as the immune-stimulatory human 
CD40 ligand. CD40L is a member of the tumor necrosis factor (TNF) 
family and enhances antigen-specific T-cell response by activating anti-
gen presenting cells.13 It also has direct antiproliferative and proapop-
totic effects on human bladder, cervical and ovarian carcinoma cells.14,15 
In addition, gene therapy with adenovirus expressing human DC40L 
has been successfully used for the treatment of canine malignant mela-
noma demonstrating that human CD40L is active in dogs.16
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We evaluated adverse events, biodistribution and shedding of oncolytic vaccinia virus encoding CD40 ligand in two Beagles, in 
preparation for a phase 1 trial in canine cancer patients. Dog 1 received one dose of vaccinia virus and was euthanized 24 hours 
afterwards, while dog 2 received virus four times once weekly and was euthanized 7 days after that. Dogs were monitored for 
adverse events and underwent a detailed postmortem examination. Blood, saliva, urine, feces, and organs were collected for virus 
detection. Dog 1 had mild fever and lethargy while dog 2 experienced a possible seizure 5.5 hours after first virus administration. 
Viral DNA declined quickly in the blood after virus administration in both dogs but was still detectable 1 week later by quantita-
tive polymerase chain reaction. Only samples taken directly after virus infusion contained infectious virus. Small amounts of viral 
DNA, but no infectious virus, were detected in a few saliva and urine samples. Necropsies did not reveal any relevant pathological 
changes and virus DNA was detected mainly in the spleen. The dogs in the study did not have cancer, and thus adverse events 
could be more common and viral load higher in dogs with tumors which allow viral amplification.
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We have previously described the activity of vvdd-hCD40L-tdTo-
mato in canine and feline cancer cells lines in vitro and in mouse xeno-
grafts.17 The objective of the present study was to examine safety and 
biodistribution of intravenously administered vvdd-hCD40L-tdTo-
mato in two healthy beagle dogs in preparation for a phase 1 dose 
escalation study with pet dogs that suffer from incurable cancers.
RESULTS
With the exception of possible seizure, virus administration was well 
tolerated
To evaluate possible adverse events associated with virus adminis-
tration, we monitored dogs closely according to VCOG-CTCAE v1.0 
guidelines.18 Dog 1 developed transient grade 1 fever (rectal tem-
perature 39.5 °C) 8 hours after virus infusion. The fever resolved in 3 
hours but the dog was quieter than usual until he was euthanized 
the next morning. Dog 2 had a mild increase in rectal temperature as 
well, although below the threshold of a grade 1 elevation (Figure 1). 
In addition, dog 2 had a possible grade 3 seizure 5.5 hours after 
the first virus administration. The actual event was not seen by the 
personnel. Instead, barking was heard from the kennel and when 
the researcher arrived less than 1 minute later, dog 2 was lying on 
his side on the floor and dog 1 was attacking him. When dog 1 was 
removed, dog 2 did not stand up immediately. It was lifted onto 
the examination table, at which point the physical and neurologi-
cal examination did not detect any abnormalities. In the absence of 
further evidence, we scored the event as a grade 3 seizure, reduced 
the subsequent virus doses to 0.8 × 108 tissue culture infective dose 
(TCID50)/kg, and monitored the dogs by video cameras for 24 hours 
after each virus administration. No further seizures were observed.
In addition to physical examination, we assessed adverse events 
in hematological and biochemical parameters and in urinalysis. 
Laboratory tests indicated a grade 1 increase in alkaline phosphatase 
in dog 1 (Supplementary Table S1). Dog 2 exhibited a low albumin 
level (grade 1) already prior to virus injection, and although there was 
some further decrease, the values did not exceed grade 1. In addi-
tion, both dogs had low baseline bilirubin and cholesterol levels. 
Hematology and urinalysis did not reveal any obvious changes. Total 
white blood cell and differential counts are shown in Figure 2.
Viral DNA was identified in all blood samples
We measured both viral genome and infectious virus in multiple 
blood samples collected after virus infusion. Viral DNA was detected 
by quantitative polymerase chain reaction (qPCR) in the blood of 
both dogs at all time points (Figure 3), with highest amounts of viral 
DNA in the blood sample taken immediately after virus infusion. 
The viral load declined quickly during the first 4 hours after infu-
sion, but viral DNA was still detectable in the blood 1 week later. 
Using a transduction test and plaque assay, infectious virus in blood 
was only detectable immediately after virus infusion (Figure 4). 
However, although the transduction test and plaque assay were 
clearly positive for infectious virus, the amount of virus was too low 
to be reliably quantifiable with tissue culture infective dose TCID50 
analysis, suggesting low titers.
Low levels of viral DNA were detected in saliva and urine
Furthermore, we monitored viral shedding into saliva, urine, and 
feces to find out if virus could be spread via them into the environ-
ment. In qPCR, detectable but not quantifiable amounts (i.e., above 
the limit of reliable detection but below the limit of reliable quan-
titation) of viral DNA were found in three of the five saliva samples 
taken 24 hours after virus administration, and in two urinary sam-
ples (7 days after second virus dose and 24 hours after fourth virus 
dose in dog 2) (Table 1). Transduction test and plaque assay did 
not reveal infectious virus in any of the samples. Viral DNA was not 
detected in feces, or in the other saliva or urine samples collected at 
baseline, and 1, 2, or 4 days after virus administration.
Vaccinia DNA was mainly identified in the spleen
We also assessed biodistribution of the virus in canine organs post-
mortem. In the tissue samples, virus DNA was detected mainly in 
the spleen (Table 2). However, detectable, but not quantifiable 
amounts were also found in most organs of dog 1 and in the lungs 
Figure 1 Rectal temperature of the study dogs over time after each 
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Figure 2 Total white blood cell and differential count of study dogs after 
receiving oncolytic vaccinia virus. Arrows indicate virus administrations. 
(a) Dog 1 and (b) Dog 2. Bas, basophils; Eos, eosinophils; Leuk, leukocytes; 































Figure 3 Vaccinia DNA measured by qPCR in the blood of study dogs 
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of dog 2, suggesting effective systemic dissemination of the virus 
following intravenous delivery.
Blood cytokines showed no obvious alterations
As viral infections usually generate a proinflammatory response and 
cytokine production in the body, we measured selected cytokines 
in serial blood samples. However, cytokine levels were generally 
below detection level in blood and did not change after virus injec-
tion. In fact, only interleukin (IL)-2, -6, and -12p40 could be detected 
in dog 2. In dog 1, IL-2 was detectable in the baseline sample but 
declined below the limit of detection immediately after the infu-
sion. Interferon γ (IFN-γ), TNF-α, monocyte chemotactic protein-1 
(MCP-1), IL-8, and -10 were below detection limits in both dogs 
throughout the experiment.
Administration of vaccinia virus stimulated neutralizing antibodies
Neutralizing antibodies (NAbs) may influence on the treatment 
efficacy of oncolytic viruses and thus, we measured them. NAbs 
increased over time (Figure 5). At 2 weeks, the serum dilution that 
was able to block >50% of gene expression was 1:16; while at 4 
weeks, a 1:4,096 dilution was sufficient.
Virus administration did not induce any pathological changes
Toxic effects of the virus were evaluated in necropsy in addi-
tion to physical examination and laboratory measurements. The 
postmortem examination did not reveal any specific findings. Dog 
1, however, exhibited aspermatogenesis as an incidental finding 
probably not related to treatment. Immunohistochemistry for vac-
cinia virions and β-galactosidase (an inactive but immunogenic 
form of which is present in the virus) was performed on the spleen 
of both dogs, since these organs had shown the highest viral DNA 
loads. With the antivaccinia antibody, viral antigen was detected 
in the cytoplasm of a few macrophages in the red pulp, suggest-
ing phagocytosis of vaccinia virus particles (Figure 6). Staining 
with the anti-β-galactosidase antibody yielded a negative result as 
expected, since β-galactosidase is expressed only after viral replica-
tion, a feature that should not occur in nontumor bearing animals 
since the virus has been constructed to be tumor specific. Lack of 
β-galactosidase expression, compatible with lack of virus repli-
cation, is in accord with the molecular tests (e.g., qPCR) reported 
above.
DISCUSSION
Here, we report intravenous administration of oncolytic vaccinia 
virus, vvdd-hDC40L-tdTomato, to two laboratory Beagles. The infu-
sion was well tolerated and—with the possible exception of the 
unconfirmed grade 3 seizure in dog 2—only mild adverse events 
were observed. The postmortem examination did not reveal any 
significant pathological changes, and none associated with vaccinia 
virus administration.
The onset of the suspected seizure in dog 2 was not witnessed 
by the personnel, and no signs associated with a typical grand mal 
seizure, such as unconsciousness, tonic-clonic motor activity, drool-
ing, urinating, or defecating, was observed during the brief encoun-
ter with the still-prone animal, or upon physical inspection after the 
animal had recovered. However, because dog 2 did not stand up 
immediately after dog 1 was removed and because his limbs were 
extended, we classified the event as a grade 3 (involving altered 
consciousness, as dogs with generalized seizures always exhibit 
decreased consciousness) seizure per VCOG-CTCAE v1.0 guide-
lines,18 as opposed to a dog fight, which the two dogs had been 
found engaged in on some previous occasions.
Seizures have not been reported in human patients receiving 
oncolytic vaccinia virus.19–25 However, if it did occur in dog 2, the 
most likely explanation could relate to a hypersensitivity reaction 
and cytokine production associated with virus administration or 
Figure 4 Plaques detected on A549 cell monolayers overlaid with blood samples taken immediately after vvdd-tdTom-CD40L administration. Presence 
of infectious virus was demonstrated by fluorescence microscope (the red color in the upper row indicates infection by vvdd-hCD40L-tdTomato coding 
tdTomato) and with light microscopy (lysis of the monolayer present in the lower row indicates productive replication of virus rescued from dog blood). 
(a) Dog 1 after first dose and (b,c) dog 2 after third dose. Scale bar = 200 μm.
a b c
Table 1 Positive secretion samples for vaccinia DNA by 
qPCR in the study dogs
Secretion Dog Timepoint
Saliva 2 1 day after second virus dose
1 day after third virus dose
1 day after fourth virus dose
Urine 1 1 day after first virus dose
2 7 days after second virus dose
Number of DNA copies was <100/10 μl of purified DNA in all samples.
qPCR, quantitative polymerase chain reaction.
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other components in the virus preparation, since proinflammatory 
cytokines modulate brain exitability and predispose to seizures.26 
Idiopathic epilepsy is a well-known disease in dogs, and in Harlan 
colonies the incidence is ~0.1 % (S. Hillen, personal communica-
tion). However, dog 2 or his close relatives did not have any reported 
history of epilepsy. An additional theory relates to the association of 
high fever with convulsions in humans, especially in children.27 Dog 
2 only had minor increase in rectal temperature (39.3 °C), not even 
reaching grade 1, and thus this explanation seems unlikely.
The virus preparation used in our study contained detectable 
levels of host cell protein and bovine serum albumin (25.7 and 3.4 
μg/ml, corresponding to a total of 52.38 μg in the first injection of 
dog 2). All foreign proteins can induce an immune response in the 
host and the risk is increased the less homology there is between 
foreign and host protein, however, the magnitude of reaction 
is difficult to evaluate.28 For example, although human and dog 
albumin show only 91.7% homology,29 human albumin is never-
theless safely and effectively used in the treatment of critically 
ill dogs with hypoalbuminemia. In a retrospective study, none of 
418 dogs receiving human albumin at a dose of 1 g/kg/day (cor-
responding to a total amount of 145 mg of human albumin in dog 
2 in 15 minutes, i.e., 2,700-fold more than there was noncanine 
protein present in the virus injection) developed severe hyper-
sensitivity reactions or seizures that would require disruption of 
infusion or treatment.30 We therefore believe that it is unlikely that 
a small amount of human or bovine protein residues in the virus 
preparation would induce a seizure. Rather, if a seizure occurred, 
the relatively high dose of vaccinia virus present in the preparation 
may be a more likely cause.
Fever and lethargy are well-known symptoms in association with 
viral infection. The body temperature of dog 1 was at the lower limit 
of grade 1 fever (39.5 °C; VCOG-CTCAE v1.0 grade 1 fever 39.5–40.0 
°C) and he had grade 1 lethargy. Dog 2 exhibited a mild grade 0 
increase in rectal temperature after the first virus administration 
(39.3 °C) and no lethargy. Although his temperature was not high 
enough to qualify as an adverse event, in theory this may have 
been associated with the possible seizure, as it is known that epi-
leptic seizures can increase body temperature.31 Fever and lethargy 
are amongst the most common adverse events reported in cancer 
patients receiving oncolytic virotherapy19–25 and result from the 
innate immune response to virus.9,32
Hematology and differential blood count did not show any 
obvious changes in either dog in the study. Histologic evalu-
ation of the bone marrow collected in the necropsies did not 
reveal any signs of toxicity either. This is in contrast to the results 
of Park et al.24 who reported transient decrease in lymphocytes, 
platelets and red blood cells during the first 3 days after onco-
lytic vaccinia virus (JX-594) treatment of patients with primary or 
metastatic liver cancer. In addition, they reported neutrophilia in 
9 of 14 patients. Heo et al.20 also reported lymphopenia in 4 of 
30 patients and a decrease in hemoglobin in 3 of 30 liver can-
cer patients treated with JX-594. Lymphopenia was also found 
in healthy beagle dogs receiving recombinant oncolytic vesicu-
lar stomatitis virus VSV-IFNβ-NIS,33 but the lymphocyte drop was 
only seen in one of six healthy dogs receiving oncolytic adeno-
virus.34 Viral infections are often associated with lymphopenia, 
and it has been suggested that this phenomenon is associated 
with type 1 IFNs, the principal cytokines involved in viral infec-
tion, leading to attachment of lymphocytes to the endothelium, 
without migration into tissues.35 An obvious reason for the lack of 
hematological effects in our dogs is the lack of tumors in them, 
resulting in no amplification of input virus.
As expected, the vaccinia virus genome copy number was high-
est in the blood samples taken immediately after virus infusion and 
declined quickly thereafter. In contrast to studies in human cancer 
patients,20,21,24 there was no secondary viremia peak, which is com-
patible with tumor-restricted replication of the virus and thus lack 
of replication in these dogs. We found infectious virus only in blood 
collected immediately after virus infusion. One aspect which may 
impact on the infectiousness of vaccinia in circulation relates to the 
complement system and the innate immune response. Sampath 
et al.36 showed that complement severely inhibited vaccinia virus 
delivery, and we also found decreased infectivity of vaccinia virus 
when incubated with canine blood. It may be of importance the 
infectious viruses could be detected in intact dog blood; systemic 
exposure to infectious tumor selective virus could be useful for 
treatment of metastatic disease.




1 Spleen 9.9 × 105
Adrenal glands, aorta, bone and joint, epididymis, esophagus, gallbladder, gingiva, heart, kidneys, 
pancreas, sciatic nerve, pituitary gland, prostate, salivary gland, muscle, testes, thyroid, tongue, trachea
<100
2 Spleen 3.9 × 106
Lungs <100
qPCR, quantitative polymerase chain reaction.
Figure 5 Transduction inhibition by serum neutralizing antibodies in 
dog 2. Blood samples were collected at baseline (0 week), 2, 3, and 4 
weeks after first virus dose. A549 cells were challenged in triplicate 
with a mixture of vvdd-luc preincubated with heat inactivated serum. 
Luciferase expression was measured 20 hours after infection. Values are 
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We observed aspermatogenesis in dog 1, but consider it highly 
unlikely that this was a consequence of virus administration, since 
the dog was euthanized 24 hours after virus infusion and in dogs 
each spermatogenic cycle lasts ~2 weeks, and spermatogenesis 2 
months.37 Considering the fact that despite its role as a breeder, dog 
1 did not have any offspring (S. Hillen, personal communication), 
aspermatogenesis was likely present prior to virus injection.
A few human cancer patients receiving oncolytic vaccinia virus 
have been reported to develop pox-like skin lesions.19,20 Skin lesions 
were also reported in laboratory beagles receiving intradermal 
inoculation of TK-deleted vaccinia virus (VTK-79).38 The dogs receiv-
ing the virus were in close contact with dogs that did not receive the 
virus. None of those developed antibodies to the virus, suggesting 
that virus did not spread from inoculated to noninoculated dogs.
Although our virus is tumor specific and thus not capable of caus-
ing systemic vaccinia infections, we assessed both dogs for poten-
tial virus shedding into the environment, by testing saliva, urine and 
feces for the virus. Vaccinia virus is quite stable in organic material 
in the environment. For example, it was possible to detect infective 
vaccinia virus from a scab collected from a small pox vaccination site 
and saved for 13 years in an envelope in the laboratory cupboard.39 
In addition, infectious small pox virus was found in the household of 
a vaccinated person 10 days after he had left the house.40 The dogs 
in our study exhibited small amounts of vaccinia genomes in a few 
saliva and urine samples. However, the dogs used in the study did 
not carry tumors, and it is possible that the viral load may be higher 
in dogs with tumors that allow the virus to amplify. Consequently, 
our trial protocol will request the owners to prevent the dogs from 
licking humans, in case a pet dog will be treated with oncolytic vac-
cinia virus.
Urine may also pose a risk for spreading of the virus in environ-
ment, since pet dogs urinate outside and it is difficult to collect all 
urine. In one study, it was reported that vaccinia virus remained 
infectious for 4 months at +4 °C in water.41 In our dogs, only two 
urine samples were positive for vaccinia DNA and neither contained 
infectious virus.
In feces, which have been reported in mice to retain infectious 
vaccinia virus for up to 20 days at room temperature,42 we did not 
identify vaccinia virus genomes. Also, feces pose less of a biosafety 
issue as stools are easier to collect and discard.
Shedding of JX-594, an oncolytic vaccinia virus of the Wyeth strain 
featuring a TK-deletion and expression of hGM-CSF and LacZ genes, 
was not found in urine or throat swabs from 14 patients in a phase 
1 trial,24 but virus was detected in throat swabs in a subsequent trial 
(EudraCt 2011-000051-16). Shedding of another oncolytic vaccinia 
virus, GL-ONC-1, was detected in urine, feces and sputum in 1 out of 
27 patients.22 A third vaccinia virus, vvDD-CDSR, was not detected 
in any of the excretion samples analyzed.25 Thus, the available evi-
dence suggests that vaccinia virus genomes can occasionally be 
detected in excretions of both dogs and humans, representing 
probably DNA fragments from virus digested by white blood cells, 
but identifying infectious virus is rare.
As reported for humans,19–24 vaccinia virus induced NAbs also in 
our study. The effects of antiviral antibodies in cancer gene therapy 
remain unclear. Clinical evidence from humans treated with oncolytic 
adenoviruses seems to contradict the classical viewpoint that anti-
bodies would compromise gene delivery and efficacy, since baseline 
antibody titers seem to correlate with efficacy instead of the oppo-
site.43–45 Nevertheless, it may be of relevance that vaccinia virus pres-
ents also as an extracellular enveloped form which can avoid anti-
body formation,36 facilitating spread of the virus to metastatic lesions.
Since we only had two dogs included into this preliminary exper-
iment, the power of the study in minimal and the results cannot 
be extrapolated to other dogs. However, our results show that it is 
Figure 6 Detection of vaccinia virus antigen by immunocytochemistry. (a,b) Dog 1, spleen. (a) A few macrophages are found to express viral antigen 
(arrows). (b) In the negative control section (omission of primary antibody), no reaction is seen. (c,d) Mouse tumor xenografts treated with intratumoral 
injection of vaccinia virus are shown as a positive control. (c) Tumor cells express viral antigen (arrows). (d) In the negative control section (omission of 
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possible to give high dose of oncolytic vaccinia virus intravenously 
for a healthy dog without lethal or otherwise serious adverse 
events even multiple times. Further safety evaluation could be 
done with healthy laboratory dogs; however, in our opinion dogs 
with naturally occurring incurable cancers offer more reliable and 
ethical model, since the virus replicates in tumor tissues. Thus, we 
have opened a phase 1 clinical evaluate safety, adverse events, and 
shedding of the virus in tumor-bearing client-owned dogs. Virus 
is given intratumorally and the starting dose will be lower than in 
this study. The dogs will be carefully monitored for seizures, to shed 
light on the possible linkage of treatment with the unexpected 
event described here. Also, a phase 1 clinical study of another 
oncolytic vaccinia virus, V-VET1 (also called LIVP6.1.1), has been 
started in pet dogs in the United States in 2012, evaluating intrave-
nous administration of the virus. V-VET1 is derived from Lister strain 
vaccinia virus and has a TK disruption.46
In conclusion, administration of a high dose of oncolytic Western 
Reserve vaccinia virus vvdd-hCD40L-tdTomato seems feasible in 
dogs. The present virus design allows adverse events, efficacy, and 
biosafety to be monitored meticulously in trials.
MATERIALS AND METHODS
Dogs
Two healthy adult male HsdRcc:DOBE Beagle dogs (Harlan Laboratories, 
Gannat, France) were used (Supplementary Table S2). Both were retired 
breeding males. The experiment was approved by the National Animal 
Experiment Board of the Regional State Administrative Agency of Southern 
Finland (DNO 4953), and by the Finnish Board for Gene Technology 
(17/M/2011).
Virus and cell lines
A vaccinia virus Western Reserve strain deleted for TK and VGF and express-
ing human CD40L and tdTomato (vvdd-hCD40L-tdTomato) was designed as 
previously described.10
The virus was produced by standard sucrose gradient centrifugation in 
good manufacturing practice quality A549 cells (human lung adenocarci-
noma epithelial cell line received from National Cancer Institute) in growth 
media (GM) consisting of Dulbecco’s modified Eagle medium GM (DMEM, 
Lonza, Verviers, Belgium), 1% L-glutamine, 1% penicillin-streptomycin, and 
2% fetal calf serum (FCS) in 5% CO2 at 37 °C.
47 The infectious titer was mea-
sured by a standard median TCID50 test in A549 cells.
48
African green monkey kidney cells (Vero cells) from the American Type 
Culture Collection grown in DMEM with 4.5 g/l of glucose (Lonza) containing 
1% L-glutamine, 1% penicillin-streptomycin, and 10% FCS in 5% CO2 at 37 °C 
were used for the detection of infectious virus.
Study design
Dog 1 was randomized for the evaluation of acute toxicity and received a 
single infusion of vvdd-hCD40L-tdTomato. Dog 2 was randomized to evaluate 
toxicity following repeated virus administration and received four infusions of 
vvdd-hCD40L-tdTomato once per week. Dog 1 was euthanized 24 hours after 
virus infusion and dog 2 1 week after the fourth virus infusion. A full postmor-
tem examination was undertaken on both dogs immediately after death.
The dose we chose to use in our study was 1.2 × 108 TCID50/kg, 
which  is  approximately three times the maximum dose used (assuming a 
75 kg patient) in a phase 1 dose escalation study with another oncolytic vac-
cinia virus, JX-594, in patients with primary or metastatic liver cancer.24
The virus was diluted in 50 ml of saline (Baxter, Norfolk, UK) and infused 
via intravenous catheter into a peripheral vein over 15 minutes (200 ml/
hour). Vein access was confirmed before virus administration with 10 ml 
of saline. After virus administration, the saline bag and infusion line were 
flushed with 25 ml of saline at the same infusion rate to ensure that the dogs 
received the total planned dose of the virus.
The dogs were monitored for adverse events according to Veterinary 
cooperative oncology group—Common terminology criteria for adverse 
events v1.0 (VCOG-CTCAE v1.0).18 Attitude, respiratory and heart rate, color 
of mucous membranes, capillary refill time, rectal temperature, and blood 
pressure were monitored prior to virus administration and then every 15 
minutes and 1, 2, 4, 8, 11, and 24 hours after virus administration. The dogs 
were monitored for swelling, itching and vomiting, the most common clini-
cal signs of hypersensitivity in this species. After the first 24 hours, dog 2 had 
his attitude, appetite, weight, respiratory, and heart rate, color of mucous 
membranes, capillary refill time, and rectal temperature monitored daily.
Sample collection
Blood (3 ml) was collected into tubes containing potassium (K2) ethylenedi-
aminetetraacetic acid (EDTA) for virus detection and cytokine measurements 
from the jugular, cephalic or saphenous vein before and immediately after 
virus administration, and 1, 2, 4, 11, and 24 hours as 2, 4, and 7 days after 
each virus infusion. Saliva was collected with two cotton tips held in each 
side of the mouth for 30 seconds. Urine (5 ml) was collected by cystocentesis 
for each sample except for two times when the urine was collected from the 
kennel floor immediately after voiding due to unsuccessful cystocentesis on 
an empty bladder. Feces (5–10 g) were collected rectally or from the kennel 
latrine after defecation when rectal collection failed. Saliva, urine, and feces 
were collected on days 1, 2, 4, and 7 after virus infusion.
Blood samples were centrifuged for 10 minutes at 2,400g immediately 
after collection, plasma and cell pellet was separated, initially frozen at −18 
°C and transferred on the same day to −80 °C until analysis. Urine and fecal 
samples were frozen and stored following the same protocol.
In addition, blood was collected for (K2) EDTA tubes (1 ml) for hematology 
before virus administration and 2, 4, and 7 days after and for serum tube 
(6 ml) for clinical chemistry once weekly. In dog 1, samples were collected 
right before virus administration and euthanasia. Serum was separated after 
a minimum of 30 minutes incubation in room temperature by centrifuging 
10 minutes 2,400g and both hematology and clinical chemistry samples 
were analyzed the day they were collected.
qPCR
DNA was extracted from whole blood using a commercial kit (Gentra 
Puregene Blood Kit, QIAGEN, Germantown, MD). Saliva was diluted in 2,500 
μl of phosphate-buffered saline (BioWhittaker, Lonza) by squeezing the cot-
ton swabs against the tube walls. One milliliter of the solution was used for 
DNA extraction (Gentra Puregene Blood Kit for Body Fluids, QIAGEN) accord-
ing to the manufacturer’s instructions. DNA from the urine was extracted by 
the same method, using 1 ml of urine per sample. For feces, 180–220 mg was 
used for DNA extraction. To lyse bacteria and other pathogens and to absorb 
qPCR reaction inhibitors, samples were first subjected to the QIAamp DNA 
Stool kit (QIAGEN GmbH, Hilden, Germany) using Buffer ASL and InhibitEX 
tablets. Subsequently, the Gentra Puregene Tissue Kit (QIAGEN) was used, fol-
lowing the manufacturer’s instructions. The same tissue kit was used for tissue 
samples (see postmortem examination), using 50–100 mg of each tissue. The 
concentration of the extracted DNA was measured by spectrophotometry 
(Nanodrop 8000, Thermo Scientific, Wilmington, DE). Positive controls spiked 
with vaccinia virus were utilized to monitor the virus quantitation methods. 
Tissue and excretion samples from healthy dogs were extracted according to 
the same protocols and served as negative controls.
qPCR amplification was based on primers and probe targeting the HA J7R 
gene (OPHA-probe AGT GCT TGG TAT AAG GAG, OPHA-F89 GAT GAT GCA 
ACT CTA TCA TGT A and OPHA-R219 GTA TAA TTA TCA AAA TAC AAG ACG 
TC; Applied Biosystems UK, Cheshire, UK). Canine β-actin served as house-
keeping gene (Canine actin Probe TCC TGG CCT CAC TGT CCA CCT TCC AGC, 
Canine actin FW GCG CAA GTA CTC TGT GTG GAT, and Canine actin RV GTC 
GTA CTC CTG CTT GCT GAT; Oligomer, Helsinki, Finland). All samples were 
run in triplicate. A standard curve was generated for absolute quantification 
by using HA-vaccinia plasmid kindly donated by Prof Vapalahti, Haartman 
Institute, University of Helsinki. Water was used as a negative control. The 
limit of detection for analysis was 1 copy/30 μl whole blood, 1 copy/100 μl 
urine, and 1 copy/5 mg feces. The limit of quantification was 1 copy/3 ml 
whole blood, 1 copy/10 ml urine, and 1 copy/500 mg feces. It was not pos-
sible to define detection or quantification limits for saliva, since the amount 
of collected saliva was very low.
Detection of infectious virus
All positive saliva and urine samples and selected blood samples were eval-
uated for infective virus by plaque assay. A549 and Vero cells were plated 
on a 6 well plate at 400,000 cells per well in GM with 10% FCS. Samples 
(200 μl) were each diluted in 6 ml GM total after three freeze-thaw cycles 
and 1 ml per well was used for infection. To maximize infection, infected 
cells were centrifuged at 600g for 20 minutes at room temperature and 
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then incubated for 30 minutes in 5% CO2 at 37 °C. After infection, GM with 
10% FCS was added and plates were incubated for 3 days, upon which 
plaques were visualized by Coomassie blue staining. To confirm that canine 
saliva, urine, and blood did not prevent viral and cell growth, we performed 
plaque assays with secretions alone and with secretions spiked with virus. 
We also incubated plaque assay cells with 300 μl blood in each well for 1 
hour prior to infection. TCID50 was evaluated in selected blood samples in 
Vero cells as described above, using dilutions of 10−2–10−9, and the results 
were read on day 10.
Cytokine measurement and NAb
IFN-γ, TNF-α, IL-2, -6, -8, -10, and -12, and MCP-1 was measured in the plasma 
collected in EDTA tubes, with the Procarta Immunoassay Magnetic Bead kits 
(Affymetrix Panomix, Santa Clara, CA). To inactivate virus prior to measurement, 
50 μl QuantiGene Plex Assay Kit Lysis Mixture (Affymetrix Panomix) was added 
to 100 μl plasma. Fluorescence was measured by the Bio-Plex 200 System (Bio 
Rad, Hercules, CA) device following the manufacturer’s instructions.
NAbs were measured in serum samples from dog 2 collected 2, 3, and 
4 week after first virus infusion. A549 cells were plated on a 96-well plate 
(50,000 cells per well in DMEM with 10% FCS). The following day, serum was 
heated for 90 minutes at 56 °C to inactivate complement, and a serial four-
fold dilution was prepared in plain DMEM. Diluted serum and 100 plaque-
forming unit (PFU) of luciferase expressing double deleted vaccinia virus 
(vvdd-luc) at 4 × 103 PFU/ml were incubated for 60 minutes at room temper-
ature on an orbital shaker and added in triplicates to each well after remov-
ing old media and washing of the cells. After incubation for 60 minutes in 
5% CO2 at 37 °C, 100 μl of DMEM with 10% FCS was added to the wells, and 
the plates were incubated for 20 hours in 5% CO2 at 37 °C. After that, GM 
was removed, cells were lysed and luciferase activity was measured with the 
Luciferase Assay System (Promega, Madison, WI) using TopCount luminom-
eter (PerkinElmer, Waltham, MA) following the manufacturer’s instructions. 
The neutralizing antibody titer was defined as the highest dilution of the 
virus preventing ≥50% of the luciferase expression.
Postmortem examination, histology and immunohistology Necropsy 
was performed on both beagle dogs immediately after death, and several 
samples from skeletal muscle, bones, nervous, endocrine, cardiovascular, 
respiratory, hemolymphatic, gastrointestinal, and urogenital systems and 
the skin collected for histological examination. Tissue specimens were fixed 
in 4% paraformaldehyde for 48 hours and routine paraffin wax embedded. 
Sections (4 μm) were prepared and stained with hematoxylin and eosin for 
histological examination. Samples from the same organs were collected in 
liquid nitrogen for DNA extraction and detection of the virus by qPCR.
A rabbit antivaccinia polyclonal antibody (1:1,000; Quartett, Berlin, 
Germany) and a rabbit anti-β-galactosidase polyclonal antibody (1:3,000; 
EMD Millipore, Temecula, CA) were used as primary antibodies for the 
immunohistochemical detection of vaccinia virus. β-galactosidase is 
a protein expressed by lacZ transgene located in VGF region of vvdd-
hCD40L-tdTomato under the control of the p7.5 promoter.49 The horserad-
ish peroxidise method was applied, using the Lab Vision Biotinylated Goat 
anti-Rabbit HRP kit (Thermo Fisher Scientific, Runcorn, UK) as a secondary 
antibody and detection system. Binding of the antibodies was visualized 
with the Polydetector HRP Green Substrate-Chromogen kit (Bio SB, Santa 
Barbara, CA) and Harris hematoxylin counterstaining. PFA fixed and paraf-
fin wax embedded tumors from mice treated with vaccinia virus served as 
positive controls for the antibodies. Only the spleen from both beagle dogs 
was stained, since qPCR had shown that it contained the highest amount of 
vaccinia genome. Sections incubated without the primary antibody and sec-
tions of spleen from an untreated dog served as negative controls.
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